Detailed View
ALNY - Alnylam Pharmaceuticals, Inc.
Latest filing: 2026-06-30 | Reporting: gaap
Market Cap
33,275,650,048
Adj EBIT (TTM)
1,336,399,000
Enterprise Value
31,567,332,048
Last Price
248.68
Earnings Yield
4.23%
Return on Capital
33.03%
Capital
4,046,256,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-06-30 | 10-Q | 2026 | 1,290,948,000 | 231,441,000 |
| 2026-03-31 | 10-Q | 2026 | 1,167,175,000 | 268,636,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 1,097,033,000 | 131,718,000 |
| 2025-09-30 | 10-Q | 2025 | 1,249,026,000 | 367,982,000 |
| 2025-06-30 | 10-Q | 2025 | 773,689,000 | -16,199,000 |
| 2025-03-31 | 10-Q | 2025 | 594,189,000 | 18,077,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 593,166,000 | -105,159,000 |
| 2024-09-30 | 10-Q | 2024 | 500,919,000 | -76,905,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.